Top

Neurological Sciences

Published in:

01-11-2018 | Review Article

Clinical management of Duchenne muscular dystrophy: the state of the art

Authors: Sonia Messina, Gian Luca Vita

Published in: Neurological Sciences | Issue 11/2018

Abstract

Introduction

Duchenne muscular dystrophy (DMD) is a devastating, progressive neuromuscular disorder for which there is no cure. As the dystrophin gene is located on the X chromosome, DMD occurs predominately in males. DMD is caused by a lack of functional dystrophin protein resulting from mutations in the 2.2-Mb DMD gene, whichdisrupts the reading frame. Care considerations for DMD advocate a coordinated, multidisciplinary approach to the management of DMD in order to optimize management of the primary manifestations of DMD as well as any secondary complications that may arise.

Methods

This review provides an overview of the multidisciplinary clinical management of DMD with regard to the respiratory, cardiology, orthopedic, and nutritional needs of patients with DMD. Recent advances in novel disease-modifying treatments for DMD are also discussed with specific reference to exon skipping and suppression of premature stop codons as promising genetic therapies.

Results

The combination of multidisciplinary clinical management alongside novel gene therapiesoffers physicians a powerful armamentarium for the treatment of DMD.

Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J (2017) The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 12(1):79. https://doi.org/10.1186/s13023-017-0631-3 CrossRefPubMedPubMedCentral

Chamberlain JR, Chamberlain JS (2017) Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther 25(5):1125–1131. https://doi.org/10.1016/j.ymthe.2017.02.019 CrossRefPubMedPubMedCentral

Niks EH, Aartsma-Rus A (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17(2):225–236. https://doi.org/10.1080/14712598.2017.1271872 CrossRefPubMed

Guiraud S, Chen H, Burns DT, Davies KE (2015) Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol 100(12):1458–1467. https://doi.org/10.1113/EP085308 CrossRefPubMedPubMedCentral

Van Ruiten H, Bushby K, Guglieri M (2017) State-of-the-art advances in Duchenne muscular dystrophy. EMJ 2(1):90–99

Bushby KM, Hill A, Steele JG (1999) Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet 353(9152):557–558CrossRef

Mohamed K, Appleton R, Nicolaides P (2000) Delayed diagnosis of Duchenne muscular dystrophy. Eur J Paediatr Neurol 4(5):219–223. https://doi.org/10.1053/ejpn.2000.0309 CrossRefPubMed

van Ruiten HJ, Straub V, Bushby K, Guglieri M (2014) Improving recognition of Duchenne muscular dystrophy: a retrospective case note review. Arch Dis Child 99(12):1074–1077. https://doi.org/10.1136/archdischild-2014-306366 CrossRefPubMedPubMedCentral

Wong SH, McClaren BJ, Archibald AD, Weeks A, Langmaid T, Ryan MM et al (2015) A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. Eur J Hum Genet 23(10):1294–1300. https://doi.org/10.1038/ejhg.2014.301 CrossRefPubMedPubMedCentral

10.

Mirski KT, Crawford TO (2014) Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis. J Pediatr 165(5):1008–1010. https://doi.org/10.1016/j.jpeds.2014.07.006 CrossRefPubMed

11.

Essex C, Roper H (2001) Lesson of the week: late diagnosis of Duchenne’s muscular dystrophy presenting as global developmental delay. BMJ 323(7303):37–38CrossRef

12.

D'Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Previtali SC, Pane M, D'Angelo MG, Bruno C, Messina S, Ricci F, Pegoraro E, Pini A, Berardinelli A, Gorni K, Battini R, Vita G, Trucco F, Scutifero M, Petillo R, D'Ambrosio P, Ardissone A, Pasanisi B, Vita G, Mongini T, Moggio M, Comi GP, Mercuri E, Bertini E (2017) Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: critical issues and areas for improvements. Neuromuscul Disord 27(5):447–451. https://doi.org/10.1016/j.nmd.2017.02.006 CrossRefPubMed

13.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251–267. https://doi.org/10.1016/S1474-4422(18)30024-3 CrossRefPubMedPubMedCentral

14.

Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21(10):1049–1053. https://doi.org/10.1038/ejhg.2012.301 CrossRefPubMedPubMedCentral

15.

Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71(3):304–313. https://doi.org/10.1002/ana.23528 CrossRefPubMed

16.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77–93. https://doi.org/10.1016/S1474-4422(09)70271-6 CrossRefPubMed

17.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C, DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9(2):177–189. https://doi.org/10.1016/S1474-4422(09)70272-8 CrossRefPubMed

18.

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347–361. https://doi.org/10.1016/S1474-4422(18)30025-5 CrossRefPubMedPubMedCentral

19.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout CJ, Weber DR, Ward LM, DMD Care Considerations Working Group (2018) Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17(5):445–455. https://doi.org/10.1016/S1474-4422(18)30026-7 CrossRefPubMedPubMedCentral

20.

Van Ruiten HJ, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V et al (2016) Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in north East England. Eur J Paediatr Neurol 20(6):904–909. https://doi.org/10.1016/j.ejpn.2016.07.020 CrossRefPubMed

21.

LoMauro A, D'Angelo MG, Aliverti A (2015) Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag 11:1475–1488. https://doi.org/10.2147/TCRM.S55889 CrossRefPubMedPubMedCentral

22.

Tzeng AC, Bach JR (2000) Prevention of pulmonary morbidity for patients with neuromuscular disease. Chest 118(5):1390–1396CrossRef

23.

Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12(10):926–929CrossRef

24.

Bach JR, Martinez D (2011) Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 56(6):744–750. https://doi.org/10.4187/respcare.00831 CrossRefPubMed

25.

Ishikawa Y, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S, Minami R (2011) Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord 21(1):47–51. https://doi.org/10.1016/j.nmd.2010.09.006 CrossRefPubMed

26.

Bach JR (2017) Noninvasive respiratory Management of Patients with Neuromuscular Disease. Ann Rehabil Med 41(4):519–538. https://doi.org/10.5535/arm.2017.41.4.519 CrossRefPubMedPubMedCentral

27.

Rahbek J, Steffensen BF, Bushby K, de Groot IJ (2015) 206th ENMC international workshop: care for a novel group of patients - adults with Duchenne muscular dystrophy Naarden, the Netherlands, 23-25 may 2014. Neuromuscul Disord 25(9):727–738. https://doi.org/10.1016/j.nmd.2015.05.005 CrossRefPubMed

28.

Humbertclaude V, Hamroun D, Bezzou K, Berard C, Boespflug-Tanguy O, Bommelaer C et al (2012) Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol 16(2):149–160. https://doi.org/10.1016/j.ejpn.2011.07.001 CrossRefPubMed

29.

Fayssoil A, Abasse S, Silverston K (2017) Cardiac involvement classification and therapeutic Management in Patients with Duchenne muscular dystrophy. J Neuromuscul Dis 4(1):17–23. https://doi.org/10.3233/JND-160194 CrossRefPubMedPubMedCentral

30.

Buddhe S, Lewin M, Olson A, Ferguson M, Soriano BD (2016) Comparison of left ventricular function assessment between echocardiography and MRI in Duchenne muscular dystrophy. Pediatr Radiol 46(10):1399–1408. https://doi.org/10.1007/s00247-016-3622-y CrossRefPubMed

31.

Perri G, Filippelli S, Adorisio R, Iacobelli R, Iodice F, Testa G, Paglietti MG, D'Amario D, Massetti M, Amodeo A (2017) Left ventricular assist device as destination therapy in cardiac end-stage dystrophinopathies: midterm results. J Thorac Cardiovasc Surg 153(3):669–674. https://doi.org/10.1016/j.jtcvs.2016.08.016 CrossRefPubMed

32.

El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E, Rodrigues R, Malvankar-Mehta MS, Nguyen CT, Campbell C (2017) Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Neuromuscul Disord 27(1):4–14. https://doi.org/10.1016/j.nmd.2016.09.019 CrossRefPubMed

33.

Birnkrant DJ, Ararat E, Mhanna MJ (2016) Cardiac phenotype determines survival in Duchenne muscular dystrophy. Pediatr Pulmonol 51(1):70–76. https://doi.org/10.1002/ppul.23215 CrossRefPubMed

34.

Roberts SB, Tsirikos AI (2016) Factors influencing the evaluation and management of neuromuscular scoliosis: a review of the literature. J Back Musculoskelet Rehabil 29(4):613–623. https://doi.org/10.3233/BMR-160675 CrossRefPubMed

35.

Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ (2016) Duchenne muscular dystrophy: the management of scoliosis. J Spine Surg 2(3):185–194. https://doi.org/10.21037/jss.2016.08.05 CrossRefPubMedPubMedCentral

36.

Takaso M, Nakazawa T, Imura T, Okada T, Fukushima K, Ueno M, Takahira N, Takahashi K, Yamazaki M, Ohtori S, Okamoto H, Okutomi T, Okamoto M, Masaki T, Uchinuma E, Sakagami H (2010) Surgical management of severe scoliosis with high risk pulmonary dysfunction in Duchenne muscular dystrophy: patient function, quality of life and satisfaction. Int Orthop 34(5):695–702. https://doi.org/10.1007/s00264-010-0957-0 CrossRefPubMedPubMedCentral

37.

Chua K, Tan CY, Chen Z, Wong HK, Lee EH, Tay SK, Ong HT, Goh DY, Hui JH (2016) Long-term follow-up of pulmonary function and scoliosis in patients with Duchenne's muscular dystrophy and spinal muscular atrophy. J Pediatr Orthop 36(1):63–69. https://doi.org/10.1097/BPO.0000000000000396 CrossRefPubMed

38.

Alexander WM, Smith M, Freeman BJ, Sutherland LM, Kennedy JD, Cundy PJ (2013) The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy. Eur Spine J 22(2):411–416. https://doi.org/10.1007/s00586-012-2585-4 CrossRefPubMed

39.

Brooks JT, Sponseller PD (2016) What's new in the Management of Neuromuscular Scoliosis. J Pediatr Orthop 36(6):627–633. https://doi.org/10.1097/BPO.0000000000000497 CrossRefPubMed

40.

Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA (2013) Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 95(12):1057–1061. https://doi.org/10.2106/JBJS.L.01577 CrossRefPubMed

41.

Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M et al (2017) Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database Syst Rev 1:CD010899. https://doi.org/10.1002/14651858.CD010899.pub2 CrossRefPubMed

42.

Ma J, McMillan HJ, Karaguzel G, Goodin C, Wasson J, Matzinger MA et al (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28(2):597–608. https://doi.org/10.1007/s00198-016-3774-5 CrossRefPubMed

43.

Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM (2012) The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 23(11):2703–2711. https://doi.org/10.1007/s00198-012-1911-3 CrossRefPubMed

44.

Medeiros MO, Behrend C, King W, Sanders J, Kissel J, Ciafaloni E (2013) Fat embolism syndrome in patients with Duchenne muscular dystrophy. Neurology 80(14):1350–1352. https://doi.org/10.1212/WNL.0b013e31828ab313 CrossRefPubMed

45.

McAdam LC, Rastogi A, Macleod K, Douglas Biggar W (2012) Fat embolism syndrome following minor trauma in Duchenne muscular dystrophy. Neuromuscul Disord 22(12):1035–1039. https://doi.org/10.1016/j.nmd.2012.07.010 CrossRefPubMed

46.

Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S (2017) Nutritional challenges in Duchenne muscular dystrophy. Nutrients 9(6):594. https://doi.org/10.3390/nu9060594 CrossRefPubMedCentral

47.

Martigne L, Salleron J, Mayer M, Cuisset JM, Carpentier A, Neve V, Tiffreau V, Guimber D, Gottrand F (2011) Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. Br J Nutr 105(10):1486–1491. https://doi.org/10.1017/S0007114510005180 CrossRefPubMed

48.

Davis J, Samuels E, Mullins L (2015) Nutrition considerations in Duchenne muscular dystrophy. Nutr Clin Pract 30(4):511–521. https://doi.org/10.1177/0884533615586202 CrossRefPubMed

49.

van Bruggen HW, Van Den Engel-Hoek L, Steenks MH, Bronkhorst EM, Creugers NH, de Groot IJ, Kalaykova SI (2015) Reduced mandibular range of motion in Duchenne muscular dystrophy: predictive factors. J Oral Rehabil 42(6):430–438. https://doi.org/10.1111/joor.12274 CrossRefPubMed

50.

Diamanti A, Panetta F, Tentolini A (2011) Efficacy and safety of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 30(2):263; author reply 264. https://doi.org/10.1016/j.clnu.2010.10.004 CrossRefPubMed

51.

Martigne L, Seguy D, Pellegrini N, Orlikowski D, Cuisset JM, Carpentier A, Tiffreau V, Guimber D, Gottrand F (2010) Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 29(1):60–64. https://doi.org/10.1016/j.clnu.2009.06.009 CrossRefPubMed

52.

Toussaint M, Davidson Z, Bouvoie V, Evenepoel N, Haan J, Soudon P (2016) Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management. Disabil Rehabil 38(20):2052–2062. https://doi.org/10.3109/09638288.2015.1111434 CrossRefPubMedPubMedCentral

53.

Kraus D, Wong BL, Horn PS, Kaul A (2016) Constipation in Duchenne muscular dystrophy: prevalence, diagnosis, and treatment. J Pediatr 171:183–188. https://doi.org/10.1016/j.jpeds.2015.12.046 CrossRefPubMed

54.

Shimizu-Fujiwara M, Komaki H, Nakagawa E, Mori-Yoshimura M, Oya Y, Fujisaki T, Tokita Y, Kubota N, Shimazaki R, Sato K, Ishikawa T, Goto K, Mochizuki H, Takanoha S, Ogata K, Kawai M, Konagaya M, Miyazaki T, Tatara K, Sugai K, Sasaki M (2012) Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain and Development 34(3):206–212. https://doi.org/10.1016/j.braindev.2011.05.005 CrossRefPubMed

55.

Rybalka E, Timpani CA, Stathis CG, Hayes A, Cooke MB (2015) Metabogenic and Nutriceutical approaches to address energy dysregulation and skeletal muscle wasting in Duchenne muscular dystrophy. Nutrients 7(12):9734–9767. https://doi.org/10.3390/nu7125498 CrossRefPubMedPubMedCentral

56.

Salmaninejad A, Valilou SF, Bayat H, Ebadi N, Daraei A, Yousefi M et al (2018) Duchenne muscular dystrophy: an updated review of common available therapies. Int J Neurosci 5:1–11. https://doi.org/10.1080/00207454.2018.1430694 CrossRef

57.

Mah JK (2016) Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat 12:1795–1807. https://doi.org/10.2147/NDT.S93873 CrossRefPubMedPubMedCentral

58.

Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y (2016) Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res 8(6):2471–2489PubMedPubMedCentral

59.

Mah JK (2018) An overview of recent therapeutics advances for Duchenne muscular dystrophy. Methods Mol Biol 1687:3–17. https://doi.org/10.1007/978-1-4939-7374-3_1 CrossRefPubMed

60.

Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25(5):1069–1075. https://doi.org/10.1016/j.ymthe.2017.03.023 CrossRefPubMedPubMedCentral

61.

Syed YY (2016) Eteplirsen: first global approval. Drugs 76(17):1699–1704. https://doi.org/10.1007/s40265-016-0657-1 CrossRefPubMed

62.

The Medical Letter (2016) Eteplirsen (Exondys 51) for duchenne muscular dystrophy. Med Lett Drugs Ther 58(1507):145–146

63.

Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79(2):257–271. https://doi.org/10.1002/ana.24555 CrossRefPubMedPubMedCentral

64.

Kinane TB, Mayer OH, Duda PW, Lowes LP, Moody SL, Mendell JR (2018) Long-term pulmonary function in Duchenne muscular dystrophy: comparison of Eteplirsen-treated patients to natural history. J Neuromuscul Dis 5(1):47–58. https://doi.org/10.3233/JND-170272 CrossRefPubMedPubMedCentral

65.

Randeree L, Eslick GD (2018) Eteplirsen for paediatric patients with Duchenne muscular dystrophy: a pooled-analysis. J Clin Neurosci 49:1–6. https://doi.org/10.1016/j.jocn.2017.10.082 CrossRefPubMed

66.

Muntoni F, Frank D, Sardone V, Morgan J, Schnell F, Charleston J et al (2018) Golodirsen induces exon skipping leading to Sarcolemmal dystrophin expression in Duchenne muscular dystrophy patients with mutations amenable to exon 53 skipping (S22.001). Neurology 90(15 Supplement):S22.001

67.

European Medicines Agency Translarna (ataluren). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002720/human_med_001742.jsp&mid=WC0b01ac058001d124. Accessed 19 Mar 2018

68.

McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N et al (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10101):1489–1498. https://doi.org/10.1016/S0140-6736(17)31611-2 CrossRefPubMed

Title: Clinical management of Duchenne muscular dystrophy: the state of the art
Authors: Sonia Messina
Gian Luca Vita
Publication date: 01-11-2018
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 11/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3555-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical management of Duchenne muscular dystrophy: the state of the art

Abstract

Introduction

Methods

Results

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Please log in to get access to this content

Other articles of this Issue 11/2018

Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s Disease Questionnaire (PDQ-39-IT)

Prevalence of restless legs syndrome in individuals with migraine: a systematic review and meta-analysis of observational studies

The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study

Moyamoya complicated by thrombotic cerebrovascular accident in a Caucasian woman with collagenous colitis

Possible clinical marker of first attack of HaNDL syndrome (stroke-like mimics) in emergency room: a case report

Multiple sclerosis incidence in Tuscany from administrative data